# US 8,277,436 B2 · Vessel enlargement by arteriogenic factor delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,436 B2
- Document ID: US8277436B2
- Status: Granted
- Kind: B2
- Application number: 12/057,882
- Filed: 2008-03-28
- Published: 2008-07-24
- Granted: 2012-10-02
- Earliest claimed: 2000-12-27
- Assignees: Advanced Cardiovascular Systems, Inc.
- Inventors: Wouter Roorda
- Web page: https://patentgrep.com/patent/US8277436B2

## CPC

- A61M 25/104: {used for angioplasty}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/223: of alpha-aminoacids
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 38/043: {Kallidins; Bradykinins; Related peptides}
- A61K 38/1725: {Complement proteins, e.g. anaphylatoxin, C3a or C5a}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/1777: {Integrin superfamily}
- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61M 25/0084: {being one or more injection needles}
- A61M 2025/0086: {the needles having bent tips, i.e. the needle distal tips are angled in relation to the longitudinal axis of the catheter}
- A61M 2025/0087: {Multiple injection needles protruding laterally from the distal tip}
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of delivering an arteriogenic factor. The factor is delivered in a medically effective manner to structurally enlarge blood vessel. A distal portion of a catheter can be advanced to an existing blood vessel to deliver the arteriogenic factor.

## Claims

### Claim 1

A method comprising:
delivering an arteriogenic factor to a vessel region in a medically effective manner to structurally enlarge an existing blood vessel, wherein delivering comprises positioning a delivery device within a lumen of a bypass vessel emanating from an occluded primary vessel at a position immediately upstream from an occlusion within the primary vessel and advancing the delivery device through a wall of the bypass vessel to the vessel region, the vessel region is one of an extravascular vessel area and an intramural vessel area associated with the bypass vessel and wherein the bypass vessel and the primary vessel deliver a flow of blood to a target area.

### Claim 2 (depends on 1)

The method of claim 1, wherein the delivery comprises providing the arteriogenic factor to the vessel region as part of a degradable microparticle.

### Claim 3 (depends on 1)

The method of claim 1, wherein the arteriogenic factor is an arteriogenic chemical factor.

### Claim 4 (depends on 3)

The method of claim 3, wherein the vessel region is a tissue of an extravascular vessel area, the arteriogenic chemical factor in an amount of between about 0.01 nanograms and about 1 mg per gram of the tissue.

### Claim 5 (depends on 3)

The method of claim 3, wherein the vessel region is a tissue of an intramural vessel area, the arteriogenic chemical factor in an amount of between about 0.01 nanograms and about 1 mg per gram of the tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the arteriogenic factor is an anteriogenic chemical factor and the arteriogenic chemical factor is combined with a performance enhancing additive to promote enlargement of the existing blood vessel.

### Claim 7 (depends on 6)

The method of claim 6, wherein the performance enhancing additive enhances stability of the arteriogenic chemical factor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the arteriogenic chemical factor comprises an inflammatory selected from a group consisting of classic mediators, blood-borne molecules, cell bound molecules, endotoxins, and heavy metal compounds.

### Claim 9 (depends on 8)

The method of claim 8, wherein the classic mediators are selected from a group consisting of histamine and bradykinin.

### Claim 10 (depends on 8)

The method of claim 8, wherein the blood-borne molecules are selected from a group consisting of complement factor 5A, Platelet Activating Factor, a prostaglandin, a leukotriene, a cytokine, and Monocyte Chemoattractant Protein.

### Claim 11 (depends on 8)

The method of claim 8, wherein the cell bound molecules are selected from a group consisting of an intracellular adhesion molecule, a vascular cell adhesion molecule, a selectin, and a leukocyte integrin.

### Claim 12 (depends on 1)

The method of claim 1, wherein the arteriogenic factor is an arteriogenic physical factor, wherein said physical factor is a catheter equipped with a cutter or puncturing feature.

### Claim 13 (depends on 1)

The method of claim 1, wherein the arteriogenic factor is an arteriogenic thermal factor, wherein said thermal factor is a cryocatheter having a distal portion of between about 0° Celsius (C.) and about 10° C., or a heated catheter having a distal portion of between about 40° C. and about 99° C.

### Claim 14 (depends on 1)

The method of claim 1 wherein the bypass vessel emanates from the primary vessel at a position upstream from the occlusion within the primary vessel and terminates at the primary vessel at a position downstream from the occlusion.

### Claim 15

A method comprising:
positioning a device in a bypass vessel emanating from a primary vessel, wherein the bypass vessel emanates from the primary vessel at a position immediately upstream from an occlusion within the primary vessel and wherein each of the bypass vessel and the primary vessel deliver a flow of blood to a target area;
advancing a needle of the device through a wall of the bypass vessel to an extravascular area of the bypass vessel comprising a flow of blood; and
delivering an arteriogenic factor through the needle to the extravascular area of the bypass vessel in a medically effective manner to structurally enlarge an existing blood vessel.

### Claim 16 (depends on 15)

The method of claim 15, wherein the arteriogenic factor is an arteriogenic chemical factor in an amount between about 10 picograms and about 1 microgram per ml of the blood in the intravascular vessel area.

### Claim 17

A method of structurally enlarging an existing blood vessel, the method comprising:
advancing a distal portion of a catheter to an existing blood vessel that is a bypass vessel emanating from a primary vessel at a position immediately upstream from an occlusion within the primary vessel and wherein the bypass vessel and a primary vessel deliver a flow of blood to a target area; and
delivering an arteriogenic factor in a medically effective manner to one of an extravascular vessel area and an intramural vessel area of the existing blood vessel via a needle of the catheter advanced through a wall of the existing blood vessel.

### Claim 18 (depends on 17)

The method of claim 17, wherein the existing blood vessel has been angiogenically induced.

### Claim 19 (depends on 17)

The method of claim 17, wherein the arteriogenic factor is an arteriogenic chemical factor.

### Claim 20 (depends on 17)

The method of claim 17, wherein the arteriogenic factor is an arteriogenic physical factor, wherein said physical factor is a catheter equipped with a cutter or puncturing feature.

### Claim 21 (depends on 17)

The method of claim 17, wherein the arteriogenic factor is an arteriogenic thermal factor, wherein said thermal factor is a cryocatheter having a distal portion of between about 0° Celsius (C.) and about 10° C., or a heated catheter having a distal portion of between about 40° C. and about 99° C.
